National Comprehensive Cancer Network

Subscriptions & Products
For Patients
NCCN Compendium™
About the NCCN Compendium™
NCCN Compendium™ Chapters
Summary of Updates
No Longer Recommended Uses
JNCCN – The Journal of the National Comprehensive Cancer Network
Subscribe Now
FAQ
JNCCN Task Force Supplements

NCCN Guidelines™ & Clinical Resources

NCCN 2nd Annual Congress Hematologic Malignancies

Clinicians

Register Online

Congress Information

Program Overview

Educational Objectives

Conference Agenda

Intended Audience

Accreditation

Accommodations

Commercial Support

Exhibiting

Refer a Friend


Go back to previous page

 

 

     
 

NCCN 2nd Annual Congress:
Hematologic Malignancies™
Agenda

* Note: Agenda, presenters, and specific session times are subject to change.


Friday, September 14, 2007

7:30 – 8:45 AM

Registration, Breakfast, and Exhibits

8:45 – 8:50 AM

Welcome

Multiple Myeloma

8:55 – 9:30 AM

The Emerging Role of Novel Therapies in Initial and Subsequent Lines of Treatment
Paul G. Richardson, MD
Dana-Farber/Brigham and Women`s Cancer Center | Massachusetts General Hospital Cancer Center

9:35 – 10:05 AM

How to Treat Patients that Progress or Relapse
Seema Singhal, MD
Robert H. Lurie Comprehensive Cancer Center of
Northwestern University

10:05 – 10:25 AM

Break and Exhibits

10:25 – 10:55 AM

Treatment of Systemic Light Chain Amyloidosis
Raymond L. Comenzo, MD
Memorial Sloan-Kettering Cancer Center

Acute Myeloid Leukemia (AML)

11:00 AM – 12:00 PM

Treatment of Acute Myeloid Leukemia
Harry P. Erba, MD, PhD
University of Michigan Comprehensive Cancer Center

12:00 – 12:45 PM

Lunch and Exhibits

Non-Hodgkin’s Lymphoma (NHL)

12:45 – 1:30 PM

Cutaneous T-Cell Lymphomas
Youn H. Kim, MD
Stanford Comprehensive Cancer Center

Chronic Myelogenous Leukemia (CML)

1:35 – 2:05 PM

Update on Primary Therapy, Second-Line
Therapy, and New Agents
Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center/
Seattle Cancer Care Alliance

2:05 – 2:25 PM

Break

Myelodysplastic Syndromes (MDS)

2:25 – 3:10 PM

Implications of the 2008 WHO Reclassification
John M. Bennett, MD
University of Rochester Medical Center

3:15 – 3:35 PM

Treatment by Risk Groups
Harry P. Erba, MD, PhD
University of Michigan Comprehensive Cancer Center

3:40 – 4:00 PM

Who Would Benefit From Immunosuppressive Therapy?
Maria R. Baer, MD
The University of Maryland Greenebaum Cancer Center

4:00 – 5:30 PM

Reception


Saturday September 15, 2007

7:30 – 8:00 AM

Registration and Breakfast

Non-Hodgkin’s Lymphoma (NHL)

8:00 – 8:30 AM

Low-Grade Lymphomas
Andrew D. Zelenetz, MD, PhD
Memorial Sloan-Kettering Cancer Center

8:35 – 9:05 AM

Mantle Cell Lymphoma
Myron S. Czuczman, MD
Roswell Park Cancer Institute

Supportive Care for Patients with Hematologic Malignancies

9:10 – 9:40 AM

Transfusion Support and Iron Overload in MDS
Stephen D. Nimer, MD
Memorial Sloan-Kettering Cancer Center

9:45 – 10:15 AM

Blood Products and Growth Factors in the
Treatment of Thrombocytopenia
Farhad Ravandi, MD                  
The University of Texas MD Anderson Cancer Center

10:15 – 10:40 AM

Break

10:40 – 11:10 AM

Tumor Lysis Syndrome
David J. Straus, MD
Memorial Sloan-Kettering Cancer Center

11:15 – 11:45 AM

Skeletal Complications
Kenneth C. Anderson, MD
Dana-Farber/Brigham and Women`s Cancer Center | Massachusetts General Hospital Cancer Center

11:45 AM – 12:15 PM

Managing Infections in Patients with Hematologic Malignancies
Brahm Segal, MD
Roswell Park Cancer Institute

12:20 PM

Closing Remarks